AAV2 Immunoassay and Gene Therapy Detection Reagent

Adeno-associated virus serotype two (AAV2) holds a special place in the history of gene therapy as the first AAV serotype ever discovered and the most extensively characterized member of the AAV family. Originally isolated as a contaminant in preparations of simian adenovirus, AAV2 has since become the prototypical vector for numerous gene therapy applications and a cornerstone of viral vector research. Its well-understood biology, efficient transduction of multiple cell types, and favorable safety profile have made AAV2 the gold standard against which other serotypes are compared.Despite its many advantages, the successful development and clinical translation of AAV2-based gene therapies depend critically on accurate monitoring of host immune responses against the vector. Preexisting neutralizing antibodies and treatment-emergent anti-AAV2 antibodies can significantly reduce transduction efficiency, limit therapeutic efficacy, and pose patient safety risks. Reliable serological detection of anti-AAV2 antibodies is therefore essential for patient screening, dose stratification, and post-treatment monitoring. This page provides a comprehensive overview of AAV2 biology, its applications in gene therapy, and validated detection solutions including human and mouse anti-AAV2 antibody ELISA kits.

Figure 1.AAV2 Immunoassay.

Receptor Binding and Cell Entry

AAV2 utilizes a well-defined receptor binding cascade that has served as a model for understanding AAV entry mechanisms across serotypes. The primary attachment receptor for AAV2 is heparan sulfate proteoglycan, a highly sulfated glycosaminoglycan expressed on the surface of many cell types. Binding to heparan sulfate is mediated by clusters of basic amino acid residues on the capsid surface, including arginine and lysine residues at specific positions. Following initial attachment, AAV2 engages a secondary receptor that triggers internalization. The primary co-receptor for AAV2 is the alpha v beta 5 integrin, which binds to an arginine-glycine-aspartate motif on the capsid. Fibroblast growth factor receptor and hepatocyte growth factor receptor have also been implicated as alternative co-receptors in certain cell types. Upon co-receptor engagement, AAV2 enters cells through clathrin-mediated endocytosis, traffics through the endosomal pathway, and escapes from endosomes into the cytoplasm in a pH-dependent manner. The phospholipase A2 domain of VP1 is essential for endosomal escape, catalyzing the disruption of endosomal membranes. Following cytosolic release, AAV2 particles translocate to the nucleus through nuclear pore complexes, where the single-stranded genome is converted to double-stranded forms suitable for transcription.

Clinical Applications

Product Overview Human Anti-AAV2 Antibody ELISA Kit

The Human Anti-AAV2 Antibody ELISA Kit is designed for the quantitative or qualitative determination of total anti-AAV2 antibodies in human serum, plasma, or other biological fluids. This kit is optimized for high-throughput screening applications in clinical research and regulatory-compliant environments.

Key Features

• High Sensitivity: Detects anti-AAV2 antibodies at very low concentrations, ensuring reliable identification of low-titer seropositive samples that may be missed by less sensitive methods.
• Broad Dynamic Range: Accommodates both seronegative and high-titer samples without the need for extensive dilution optimization.
• Specificity Verified: Distinguishes anti-AAV2 antibodies from antibodies against other AAV serotypes, enabling accurate serotyping of patient samples.
• Ready-to-Use Format: Pre-coated plates with purified intact AAV2 particles, pre-diluted standards, and concentrated reagents reduce hands-on time and minimize operator error.
• Qualitative and Quantitative Options: Can be used for binary patient screening or absolute quantification of antibody concentrations using a standard curve.

Conclusions

AAV2 holds a foundational position in the field of gene therapy, serving as the prototypical vector for countless preclinical studies and several approved clinical applications. Its well-understood biology, efficient transduction of diverse cell types, and exceptional safety profile have made AAV2 an indispensable tool for gene delivery. The vector has demonstrated clinical efficacy in retinal disorders, hemophilia, spinal muscular atrophy, and other conditions, establishing the therapeutic potential of AAV-mediated gene therapy. However, the high prevalence of preexisting neutralizing antibodies and the potential for treatment-emergent immune responses pose significant challenges to the successful clinical application of AAV2-based therapeutics. The Human Anti-AAV2 Antibody ELISA Kit and Mouse Anti-AAV2 Antibody ELISA Kit provide validated, ready-to-use solutions for serological screening and immunogenicity monitoring, offering high sensitivity, specificity, and reproducibility. These tools enable accurate patient selection, dose optimization, and longitudinal monitoring of immune responses, supporting the development of safer and more effective AAV2-based gene therapies. As the field continues to advance toward clinical applications for an expanding range of indications, reliable anti-AAV2 serology will remain an essential component of successful gene therapy programs.

Anti-AAV2 Virus ELISA Kits

Anti-AAV2 Virus Antibody